Chevy Chase Trust Holdings LLC Sells 4,725 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Chevy Chase Trust Holdings LLC cut its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 106,588 shares of the medical equipment provider's stock after selling 4,725 shares during the quarter. Chevy Chase Trust Holdings LLC owned about 0.05% of Zimmer Biomet worth $11,259,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Equity Investment Corp bought a new position in shares of Zimmer Biomet in the 3rd quarter worth about $70,104,000. Hotchkis & Wiley Capital Management LLC grew its stake in Zimmer Biomet by 49.1% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider's stock worth $189,161,000 after purchasing an additional 577,320 shares during the period. Van ECK Associates Corp increased its holdings in Zimmer Biomet by 12.4% in the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider's stock worth $391,239,000 after purchasing an additional 411,163 shares in the last quarter. Thompson Siegel & Walmsley LLC acquired a new position in Zimmer Biomet in the third quarter valued at approximately $41,588,000. Finally, FMR LLC boosted its holdings in shares of Zimmer Biomet by 27.6% during the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider's stock worth $80,999,000 after buying an additional 162,384 shares in the last quarter. Institutional investors own 88.89% of the company's stock.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of research reports. Stifel Nicolaus boosted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. JMP Securities restated a "market outperform" rating and issued a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Raymond James dropped their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Finally, Royal Bank of Canada reduced their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus price target of $124.15.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH traded up $1.13 during midday trading on Wednesday, reaching $103.31. The company's stock had a trading volume of 2,236,659 shares, compared to its average volume of 1,916,930. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a market capitalization of $20.57 billion, a P/E ratio of 23.22, a PEG ratio of 1.89 and a beta of 1.02. The firm has a 50 day moving average price of $105.96 and a 200-day moving average price of $107.51. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the firm posted $2.20 earnings per share. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.93%. The ex-dividend date was Monday, December 30th. Zimmer Biomet's dividend payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.